GBT Global Blood Therapeutics Inc.

-1.74  -3%
Previous Close 56.59
Open 56.35
Price To Book 5.39
Market Cap 3089275796
Shares 56,322,257
Volume 1,259,063
Short Ratio
Av. Daily Volume 654,259

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a discontinuation announced October 23, 2017 due to lack of efficacy.
Hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest
Pre-NDA meeting scheduled for 1Q 2019. NDA to be filed under accelerated approval.
Sickle cell disease
Phase 2 data to be presented at ASH December 3, 2018 noted 55% (6 of 11) achieved a hemoglobin response >1 g/dL .
Sickle cell disease - children age 6-17.

Latest News

  1. GBT Announces New Employment Inducement Grants
  2. GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
  3. Announcing: Global Blood Therapeutics (NASDAQ:GBT) Stock Increased An Energizing 211% In The Last Three Years
  4. Detailed Research: Economic Perspectives on Intelsat S.A, Sprint, Restaurant Brands International, Tower Semiconductor, TE Connectivity, and Global Blood Therapeutics — What Drives Growth in Today's Competitive Landscape
  5. GBT Announces Participation at the Cowen and Company 39th Annual Health Care Conference
  6. Aiming at genetic diseases, Peninsula stealth biotech emerges with $191 million
  7. GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2018 Financial Results
  8. GBT Announces Participation at the 8th Annual SVB Leerink Global Healthcare Conference
  9. GBT Launches ACCEL Grants Program to Improve Access to Care for People with Sickle Cell Disease
  10. Why Global Blood Therapeutics Surged 16.7% Higher in January
  11. 6 Biotech Stocks to Watch Now
  12. GBT Announces Publication of Data from Phase 1/2 Study of Voxelotor in Patients with Sickle Cell Disease
  13. Should You Sell CRISPR Therapeutics Following an Analyst Downgrade?
  14. GBT to Present at the 37th Annual J.P. Morgan Healthcare Conference
  15. GBT Appoints Dawn Svoronos to Board of Directors
  16. Ghost Tree Capital’s AUM, Returns and Holdings
  17. Top 6 Performing IPOs of 2015 (ONCE, GBT)